The Calmer Co eyes growth in the Alcohol-Free market

Alterity advances ATH434 toward pivotal phase three MSA trial

Alterity Therapeutics is entering a pivotal phase as it prepares for a global Phase 3 trial of ATH434, a potential first-in-class treatment for multiple system atrophy. In this episode, CEO David Stamler discusses promising Phase 2 results, the science behind targeting toxic brain iron, upcoming regulatory milestones and why ATH434 could become a breakthrough therapy for patients facing a devastating neurodegenerative disease. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

The Calmer Co eyes growth in the Alcohol-Free market

As consumers increasingly seek alternatives to alcohol, ⁠The Calmer Co⁠ [https://thecalmerco.com?utm_source=chatgpt.com] is working to broaden awareness and accessibility of kava-based products in Australia and overseas. CEO Zane Yoshida joins Tim Boreham to discuss the company's latest product launch, changing consumer preferences, growth opportunities in key markets, and the role kava could play in the expanding wellness and functional beverage sectors. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Health Kick Podcast: Aroa Biosurgery (ASX:ARX)

In this episode Tim chats to of James Agnew, CFO of Aroa Biosurgery (ASX:ARX) Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Health Kick Podcast: Health Food Symmetry

In this episode Tim chats to Gordon Edwards, CEO of Health Food Symmetry Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Health Kick Podcast: The Calmer Co (ASX:CCO)

In this episode Tim chats to  Zane Yoshida, CEO and Founder of The Calmer Co (ASX:CCO) Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]